OBJECTIVE: To determine the relationship between mutations in dhfr and dhps and SP treatment failure in Plasmodium falciparum malaria in the Democratic Republic of the Congo (DRC). METHODS: Therapeutic efficacy trial was conducted in Rutshuru, Eastern DRC, between June and September 2002, comparingsulfadoxine-pyrimethamine (SP), SP plus amodiaquine (AQSP) and artesunate plus SP (ASSP) regimens for treating malaria in children under 5 years old. We genotyped 212 samples for mutations associated with SP resistance and investigated their association with treatment failure. RESULTS: In the SP arm, 61% of the subjects experienced treatment failure after 14 days. The failure rate was lower in the combination arms (AQSP: 32%, ASSP: 21%). The dhfr-108 and dhfr-51 mutations were nearly universal while 89% of the samples had at least one additional mutation at dhfr-59, dhps-437 or dhps-540. Dhps mutations had a bigger impact on treatment failure in children with high parasite density: for children with a parasite density <45 000 parasites/microl, the risk of treatment failure was 37% for mutations at dhps-437 and dhps-540 mutation and 21% for neither mutation [risk difference (RD) = 17%, 95% CI: -3%, 36%]. In children with a parasite density >45 000 parasites/microl, the treatment failure risk was 58% and 8% for children with both mutations or neither mutation, respectively (RD = 51%, 95% CI: 34%, 67%). CONCLUSIONS: Dhps-437 and dhps-540 are strongly associated with SP treatment failure and should be evaluated further as a method for surveillance of SP-based therapy in DRC.
RCT Entities:
OBJECTIVE: To determine the relationship between mutations in dhfr and dhps and SP treatment failure in Plasmodiumfalciparum malaria in the Democratic Republic of the Congo (DRC). METHODS: Therapeutic efficacy trial was conducted in Rutshuru, Eastern DRC, between June and September 2002, comparing sulfadoxine-pyrimethamine (SP), SP plus amodiaquine (AQSP) and artesunate plus SP (ASSP) regimens for treating malaria in children under 5 years old. We genotyped 212 samples for mutations associated with SP resistance and investigated their association with treatment failure. RESULTS: In the SP arm, 61% of the subjects experienced treatment failure after 14 days. The failure rate was lower in the combination arms (AQSP: 32%, ASSP: 21%). The dhfr-108 and dhfr-51 mutations were nearly universal while 89% of the samples had at least one additional mutation at dhfr-59, dhps-437 or dhps-540. Dhps mutations had a bigger impact on treatment failure in children with high parasite density: for children with a parasite density <45 000 parasites/microl, the risk of treatment failure was 37% for mutations at dhps-437 and dhps-540 mutation and 21% for neither mutation [risk difference (RD) = 17%, 95% CI: -3%, 36%]. In children with a parasite density >45 000 parasites/microl, the treatment failure risk was 58% and 8% for children with both mutations or neither mutation, respectively (RD = 51%, 95% CI: 34%, 67%). CONCLUSIONS:Dhps-437 and dhps-540 are strongly associated with SP treatment failure and should be evaluated further as a method for surveillance of SP-based therapy in DRC.
Authors: Walter M Kazadi; Sirenda Vong; Burstein N Makina; Jean C Mantshumba; Willy Kabuya; Benoit I Kebela; Nkuku P Ngimbi Journal: Trop Med Int Health Date: 2003-10 Impact factor: 2.622
Authors: Francesco Checchi; Patrice Piola; Cara Kosack; Elisa Ardizzoni; Derryck Klarkowski; Eric Kwezi; Gerardo Priotto; Suna Balkan; Nathan Bakyaita; Alan Brockman; Jean-Paul Guthmann Journal: Trop Med Int Health Date: 2004-04 Impact factor: 2.622
Authors: Ambrose O Talisuna; Anne Nalunkuma-Kazibwe; Peter Langi; Theonest K Mutabingwa; William W Watkins; Eric Van Marck; Thomas G Egwang; Umberto D'Alessandro Journal: Infect Genet Evol Date: 2004-12 Impact factor: 3.342
Authors: V Sinou; L Tshilolo Muepu Malaika; N Taudon; R Lwango; S Sese Alegre; L Bertaux; F Sugnaux; D Parzy; A Benakis Journal: Eur J Drug Metab Pharmacokinet Date: 2009 Jul-Sep Impact factor: 2.441
Authors: Maryline Bonnet; Ingrid van den Broek; Michel van Herp; Pedro Pablo Palma Urrutia; Chantal van Overmeir; Juliet Kyomuhendo; Célestin Nsibu Ndosimao; Elizabeth Ashley; Jean-Paul Guthmann Journal: Malar J Date: 2009-08-10 Impact factor: 2.979
Authors: Emmanuelle Espié; Angeles Lima; Benjamin Atua; Mehul Dhorda; Laurence Flévaud; Eric M Sompwe; Pedro Pablo Palma Urrutia; Philippe J Guerin Journal: Malar J Date: 2012-05-25 Impact factor: 2.979
Authors: Marie A Onyamboko; Steven R Meshnick; Lawrence Fleckenstein; Matthew A Koch; Joseph Atibu; Victor Lokomba; Macaya Douoguih; Jennifer Hemingway-Foday; David Wesche; Robert W Ryder; Carl Bose; Linda L Wright; Antoinette K Tshefu; Edmund V Capparelli Journal: Malar J Date: 2011-02-28 Impact factor: 2.979
Authors: Steve M Taylor; Jane P Messina; Carla C Hand; Jonathan J Juliano; Jeremie Muwonga; Antoinette K Tshefu; Benjamin Atua; Michael Emch; Steven R Meshnick Journal: PLoS One Date: 2011-01-31 Impact factor: 3.240
Authors: Sankar Sridaran; Shannon K McClintock; Luke M Syphard; Karen M Herman; John W Barnwell; Venkatachalam Udhayakumar Journal: Malar J Date: 2010-08-30 Impact factor: 2.979
Authors: Cristina Mendes; Patrícia Salgueiro; Vicenta Gonzalez; Pedro Berzosa; Agustin Benito; Virgílio E do Rosário; Bruno de Sousa; Jorge Cano; Ana Paula Arez Journal: Malar J Date: 2013-03-27 Impact factor: 2.979
Authors: Steve M Taylor; Alejandro L Antonia; Christian M Parobek; Jonathan J Juliano; Mark Janko; Michael Emch; Md Tauqeer Alam; Venkatachalam Udhayakumar; Antoinette K Tshefu; Steven R Meshnick Journal: Sci Rep Date: 2013-01-30 Impact factor: 4.379